Yau et al. [16] found that the use of ILK inhibitor QLT0254, combined with gemcitabine, could increase the drug sensitivity of gemcitabine in a mouse model of orthotopic pancreatic tumors. The gene discussed is ILK; the disease is pancreatic neoplasm.